Evidence map›Paper›PMID 28346714›Full record

ArticleTransplant international : official journal of the European Society for Organ Transplantation2017

Discrepant serological assays for Pneumococcus in renal transplant recipients - a prospective study.

Jay A Fishman, David N Iklé, Robert A Wilkinson

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Transplant international : official journal of the European Society for Organ Transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00307125 (B-Cell Depletion by Anti-CD20), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00307125 phase2completednot on this map

B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies Will Result in Inhibition of Alloantibody Production and Attenuation of Chronic Humoral Rejection

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2006 to 2012Enrolled757ConditionsKidney Transplant, Kidney Transplant Recipient, Graft Function/Survival, de Novo HLA Antibodies DevelopmentArmsRituximab plus immunosuppression, Placebo plus immunosuppression
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Jay A FishmanInfectious Disease Division and MGH Transplant Center, Massachusetts General Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0002-2671-3311
David N IkléRho, Chapel Hill, NC, USA.
Robert A WilkinsonInfectious Disease Division and MGH Transplant Center, Massachusetts General Hospital, Boston, MA, USA.
Massachusetts General Hospital · USRho (United States) · US

Funding

Noninvasive Markers and Transplant Outcome in HumansU01AI063594 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HEEGER, PETER SCOTT · 2004 to 2022
$66.5M
Novel Therapies to Improve Renal and Cardiac Allograft OutcomesU01AI063623 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI CHANDRAKER, ANIL · 2004 to 2013
$30.9M
Novel Therapies for Chronic Renal Allograft Dysfunction in ChildrenU01AI077816 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI HARMON, WILLIAM E. · 2008 to 2012
$4.8M
NIAID NIH HHS U01 AI063594NIAID NIH HHS U01 AI063623NIAID NIH HHS U01 AI077816
6 · The paper itself

Abstract

Vaccine immunoprotection for Streptococcus pneumoniae is mediated by opsonizing antibodies targeting serotype-specific capsular polysaccharides. Quantitative antibody levels enzyme-linked immunosorbent assay (ELISA) and antibody-mediated opsonophagocytic assays (OPA) measure vaccine-induced protection; correlation of these assays in transplantation requires investigation. This study examines the laboratory assessment of antibody titers in vaccinated renal recipients. Streptococcus pneumoniae 19A is common in immunocompromised hosts and is represented in protein-conjugate vaccines (PCV) and polysaccharide vaccines (PSV). Antibodies to 19A in serial sera from 30 vaccinated renal transplant recipients were compared using ELISA and OPA assays. Subject titers were classified as protected or not by ELISA (>0.35 μg/ml) and OPA titer (>1:8). Antibody titers analyzed using McNemar's test indicate that protection measured by the two assays are not the same (P = 0.0078); simple linear regression of within-subject geometric means of 19A enzyme-linked immunosorbent assay (ELISA) antibody levels versus 19A opsonophagocytic assays (OPA) titers demonstrates significant correlation between the two assays (P < 0.001). Vaccination is increasingly important given increasing antimicrobial resistance worldwide. OPA and ELISA antibody assays do not correlate well using current values for protective immunity against the Pneumococcus in immunosuppressed transplant recipients. Future studies of vaccination in transplant recipients should evaluate protective antibody levels using both functional antibody assays and standard ELISA antibody titers. (ClinicalTrials.gov: NCT00307125).

Indexed as

AdultAntibodies, BacterialEnzyme-Linked Immunosorbent AssayHumansImmunoassayImmunocompromised HostKidney TransplantationPneumococcal InfectionsPneumococcal VaccinesProspective StudiesSerologic TestsStreptococcus pneumoniaeTransplant RecipientsAntibodies, BacterialPneumococcal Vaccinesantibody titerantimicrobial resistanceenzyme-linked immunosorbent assayopsonophagocytic assaypneumococcal vaccineprotective immunity

Identifiers

PMID28346714
PMCPMC5513779
OpenAlexW2604003383

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.